Evidence Hub

Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects

ClinicalTrials.gov · COMPLETED, 2008

85 participants

Abstract

The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)

Conditions: Antivirals/HIV.

Primary outcome: Average Area Under the Plasma Concentration-time Curve for 24 Hours (AUC24avg) for Rifabutin (RIB); Maximum Plasma Concentration (Cmax) of RIB; Minimum Plasma Concentration (Cmin) of RIB; AUC24avg for 25-O-Desacetyl-RIB; Cmax of 25-O-Desacetylrifabutin (25-O-Desacetyl-RIB); Cmin of 25-O-Desacetyl-RIB; Total Area Under the Plasma Concentration-time Curve (AUCtot).

Enrollment: 85 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 85 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free